Epidermal growth factor receptors (EGFR) are a group of
receptor tyrosine kinase (RTK) that plays a major role in cell proliferation,
survival and differentiation. In most of the cancer, EGFR are amplified and
overexpressed, due to dysregulation, resulting in cancer development.
EGFR inhibitors therapies have shown improvement by
inhibiting receptor signalling and enhancing the effects of radiation therapy
and conventional chemotherapy with their anti-tumor activity. Cetuximab,
Panitumumab, Erlotinib and Afatinib are some of the major marketed drugs as
anti-EGFR therapies for the treatment of colorectal cancer, head and neck
cancer and non-small cell lung cancer.
Download Free PDF Sample Copy:
The report provides a comprehensive understanding of the pipeline
activities covering all drug candidates under various stages of development,
with detailed analysis of pipeline and clinical trials. Pipeline analysis of
drugs by phases includes product description and development activities
including information about clinical results, designations, collaborations,
licencing, grants, technology and others.
No comments:
Post a Comment